Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs
| Autor: | Johnna Perdrizet, Michele Wilson, Warisa Wannaadisai, Kevin Apodaca, Lindsay Grant |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2024 |
| Předmět: | |
| Zdroj: | Expert Review of Vaccines, Vol 23, Iss 1, Pp 879-886 (2024) |
| Druh dokumentu: | article |
| ISSN: | 14760584 1744-8395 1476-0584 |
| DOI: | 10.1080/14760584.2024.2409662 |
| Popis: | Objectives The 13-valent (PCV13) and 10-valent (PCV10) pneumococcal conjugate vaccines missed non-inferiority for certain 7-valent (PCV7) serotypes in immunogenicity trials. This study examines the population-level IPD case trends for these serotypes.Methods We identified six countries with national IPD surveillance data that introduced PCV13 (Canada, Germany, Israel, Italy, South Africa, and the United States) and three with PCV10 (Finland, Brazil, and the Netherlands). We extracted country-specific annual IPD case counts for PCV7 serotypes that missed non-inferiority and met non-inferiority (6B + 23F and PCV7 minus [6B + 23F] serotypes for PCV10 countries; 6B +9V + 23F, and PCV7 minus [6B +9V + 23F] serotypes for PCV13 countries) in clinical trials. Case count data for each country were plotted for observed serotype trends in different age groups ( |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|